International Stem Cell Corporation
International Stem Cell Corporation (ISCO) Revenue
Annual & quarterly revenue history · segment & region breakdown
ISCO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsInternational Stem Cell Corporation trailing twelve-month (TTM) revenue is $0.01B, an increase of 0.17% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.00B | +0.17% |
| 2024-12-31 | $0.01B | +$0.00B | +16.64% |
| 2023-12-31 | $0.01B | -$0.00B | -4.78% |
| 2022-12-31 | $0.01B | +$0.00B | +13.99% |
| 2021-12-31 | $0.01B | +$0.00B | +0.67% |
| 2020-12-31 | $0.01B | -$0.00B | -24.75% |
| 2019-12-31 | $0.01B | -$0.00B | -14.58% |
| 2018-12-31 | $0.01B | +$0.00B | +48.73% |
| 2017-12-31 | $0.01B | +$0.00B | +4.06% |
| 2016-12-31 | $0.01B | -$0.00B | -5.11% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income International Stem Cell Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
International Stem Cell Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from International Stem Cell Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ISCO revenue · 4 questionsISCO's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 0.17% year-over-year from $0.01B in FY2025.
▸ Source: FMP · International Stem Cell Corporation SEC filings · GAAP · International Stem Cell Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026